

| | | | | | | |
|------------|---|---|---|---|---|-------------|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Lower Risk | | | | | | Higher Risk |

JPMorgan Funds -

Global Healthcare Fund

Class: JPM Global Healthcare C (acc) - USD

Fund overview

| | | |
|---|-----------------------|-----------------------------|
| ISIN | Bloomberg | Reuters |
| LU0432979887 | JPHLUCA LX | LU0432979887.LUF |
| Investment objective: To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. | | |
| Investment approach <ul style="list-style-type: none">• Uses a fundamental, bottom-up stock selection process.• Investment process built on stock level analysis by a global research team.• Targets innovative and attractively valued companies using strong scientific rationale as the basis for all investment decisions. | | |
| Portfolio manager(s) | Fund assets | Domicile Luxembourg |
| Dominic Valder Bartjan van Hulten | USD 3788.1m | Entry/exit charges |
| Fund reference | Fund launch | Entry charge (max) 0.00% |
| currency USD | 2 Oct 2009 | Exit charge (max) 0.00% |
| Share class | NAV USD 661.77 | Ongoing charge 0.98% |
| currency USD | Class launch | |
| | 2 Oct 2009 | |
| ESG information | | |
| ESG approach - ESG Promote Promotes environmental and / or social characteristics. | | |
| SFDR classification: Article 8 "Article 8" strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective. | | |


Fund ratings *As at 31 December 2025*

Morningstar Category™ Sector Equity Healthcare

Performance

- 1 **Class:** JPM Global Healthcare C (acc) - USD
2 **Benchmark:** MSCI World Healthcare Index (Total Return Net)

Growth of USD 100,000 *Calendar years*



Calendar Year Performance (%)

| | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|--------|-------|------|-------|-------|-------|-------|------|-------|-------|
| 1 | -14.82 | 20.95 | 3.25 | 22.23 | 24.42 | 11.88 | -8.64 | 3.47 | -1.79 | 15.03 |
| 2 | -6.81 | 19.80 | 2.51 | 23.24 | 13.52 | 19.80 | -5.41 | 3.76 | 1.13 | 14.83 |

Return (%)

| | Cumulative | | | | Annualised | | |
|---|------------|----------|--------|-------|------------|---------|----------|
| | 1 month | 3 months | 1 year | YTD | 3 years | 5 years | 10 years |
| 1 | -1.04 | 13.02 | 15.03 | 15.03 | 5.34 | 3.62 | 6.81 |
| 2 | -0.79 | 10.60 | 14.83 | 14.83 | 6.41 | 6.43 | 8.14 |

Performance Disclosures

Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.

ESG

For more information on our approach to sustainable investing at J.P. Morgan Asset Management please visit <https://am.jpmorgan.com/lu/esg>


Portfolio analysis

| Measurement | 3 years | 5 years |
|---------------------------|---------|---------|
| Correlation | 0.94 | 0.91 |
| Alpha (%) | -1.01 | -2.63 |
| Beta | 1.03 | 0.95 |
| Annualised volatility (%) | 13.78 | 14.08 |
| Sharpe ratio | 0.09 | 0.09 |
| Tracking error (%) | 4.70 | 5.85 |
| Information ratio | -0.18 | -0.44 |

Holdings

| Top 10 | Sector | % of assets |
|-------------------|----------------------------------|-------------|
| Eli Lilly | Pharmaceuticals | 7.6 |
| Johnson & Johnson | Pharmaceuticals | 6.6 |
| AbbVie | Biotechnology | 5.9 |
| AstraZeneca | Pharmaceuticals | 5.2 |
| Merck & Co | Pharmaceuticals | 4.8 |
| Danaher | Life Sciences Tools & Services | 3.5 |
| UnitedHealth | Health Care Providers & Services | 3.1 |
| Medtronic | Health Care Equipment & Supplies | 3.0 |
| Novo Nordisk | Pharmaceuticals | 2.8 |
| CVS Health | Health Care Providers & Services | 2.7 |

Market cap (%) (USD)



Figures shown may not add up to 100 due to rounding.

| Regions (%) | Compared to benchmark |
|----------------------------|-----------------------|
| North America | 71.9 +0.5 |
| Europe & Middle East ex UK | 19.1 +0.9 |
| United Kingdom | 5.8 +0.3 |
| Japan | 2.5 -1.1 |
| Emerging Markets | 0.3 +0.3 |
| Pacific ex-Japan | 0.0 -1.3 |
| Cash | 0.4 +0.4 |

Figures shown may not add up to 100 due to rounding.

| Sectors (%) | Compared to benchmark |
|----------------------------------|-----------------------|
| Pharmaceuticals | 38.3 -6.7 |
| Biotechnology | 23.4 +7.8 |
| Health Care Equipment & Supplies | 16.0 -2.9 |
| Health Care Providers & Services | 11.3 -1.0 |
| Life Sciences Tools & Services | 10.6 +3.0 |
| Health Care Technology | 0.0 -0.6 |
| Cash | 0.4 +0.4 |

Figures shown may not add up to 100 due to rounding.

Key risks

The Sub-Fund is subject to **Investment risks** and **Other associated risks** from the techniques and securities it uses to seek to achieve its objective.

The table below explains how these risks relate to each other and the **Outcomes to the Shareholder** that could affect an investment in the Sub-Fund.

Investors should also read [Risk Descriptions](#) in the Prospectus for a full description of each risk.

Investment risks *Risks from the Sub-Fund's techniques and securities*

| Techniques | Securities | |
|---------------|------------|-------------------|
| Concentration | Equities | Smaller companies |
| Hedging | | |

Other associated risks *Further risks the Sub-Fund is exposed to from its use of the techniques and securities above*

| | | |
|----------|-----------|--------|
| Currency | Liquidity | Market |
|----------|-----------|--------|

Outcomes to the Shareholder *Potential impact of the risks above*

| Loss | Volatility | Failure to meet the Sub-Fund's objective. |
|---|---|---|
| Shareholders could lose some or all of their money. | Shares of the Sub-Fund will fluctuate in value. | |

General Disclosures

Before investing, obtain and review the current prospectus, Key Information Document (KID) and any applicable local offering document. These documents, as well as the sustainability-related disclosures, the annual and semi-annual reports and the articles of incorporation, are available in English free from your financial adviser, your J.P. Morgan Asset Management regional contact, the fund's issuer (see below) or at www.jpmm.lu. A summary of investor rights is available in English at <https://am.jpmorgan.com/lu/investor-rights>. J.P. Morgan Asset Management may decide to terminate the arrangements made for the marketing of its collective investment undertakings.

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy www.jpmorgan.com/emea-privacy-policy

For additional information on the sub-fund's target market please refer to the Prospectus.

Risk Indicator - The risk indicator assumes you keep the product for 5 year(s). The risk of the product may be significantly higher if held for less than the recommended holding period.

The ongoing charge is the charge used in the EU PRIIPs KID. This charge represents the total cost of managing and operating the fund, including management fees, administrative costs, and other expenses (excluding transaction costs).The breakdown of costs are the max as detailed in the fund's prospectus. For more detailed information, please refer to the fund's prospectus and the PRIIPs KID available on our website.

Performance information

Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees.

The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation.

Indices do not include fees or operating expenses and you cannot

invest in them.

The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

Holdings information

Market Cap excludes cash.

Information Sources

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

All data is as at the document date unless indicated otherwise.

© 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The historic performance shown relates to the Share Class 'JPM Global Healthtech C (acc) – USD' which was launched on 30/06/00 prior to the merger. This Sub-Fund JPMorgan Funds - Global Healthcare Fund has been launched with the assets of the JPMorgan Investment Funds - Global Healthtech Fund which has been merged into the Sub-Fund on 02/10/09. The historical performance shown corresponds to the historical performance of the former Sub-Fund JPMorgan Investment Funds - Global Healthtech Fund.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

Issuer

JPMorgan Asset Management (Europe) S.à r.l., 6, route de Trèves, L-2633 Senningerberg, Luxembourg. B27900, corporate capital EUR 10.000.000.

Definitions

NAV Net Asset Value of a fund's assets less its liabilities per Share.

Correlation measures the strength and direction of the relationship between movements in fund and benchmark returns. A correlation of 1.00 indicates that fund and benchmark returns move in lockstep in the same direction.

Alpha (%) a measure of excess return generated by a manager compared to the benchmark. An alpha of 1.00 indicates that a fund has outperformed its benchmark by 1%.

Beta measures a fund's sensitivity to market movements (as represented by the fund's benchmark). A beta of 1.10 suggests the fund could perform 10% better than the benchmark in up markets and 10% worse in down markets, assuming all other factors remain constant. Usually the higher betas represent riskier investments.

Annualised volatility (%) measures the extent to which returns vary up and down over a given period.

Sharpe ratio performance of an investment adjusting for the amount of risk taken (compared a risk-free investment). The higher the Sharpe ratio the better the returns compared to the risk taken.

Tracking error (%) measures how much a fund's returns deviate from those of the benchmark. The lower the number the closer the fund's historic performance has followed its benchmark.

Information ratio measures if a manager is outperforming or underperforming the benchmark and accounts for the risk taken to achieve the returns. A manager who outperforms a benchmark by 2% p.a. will have a higher IR than a manager with the same outperformance but who takes more risk.